Dysplasia epiphysealis hemimelica (DEH), commonly known as Trevor disease, is a rare non-hereditary epiphyseal disorder, which is characterized by localized overgrowth of osteochondral affecting one or more ossification centers or epiphyses. DEH is an asymmetrical and abnormal development of fibrocartilage, including endochondral ossification to cease dysplasia epiphysealis hemimelica once the growth process is completed. The disorder is three times more common in males than females, and most patients are first recognized between the ages of 3 and 15 years. Dysplasia epiphysealis hemimelica mostly arises in the lower limb with the distal tibia, distal femur, distal fibula, talus, tarsal bones, and proximal tibia in the order of the frequency. Dysplasia epiphysealis hemimelica is categorized by osteocartilaginous overgrowth. The disorder primarily targets long bones of the tarsal and lower extremities of bones. The incidence of Trevor disease is 1 case per 1 million population, and the etiology of the disorder is unknown.
The global dysplasia epiphysealis hemimelica treatment market is segmented on the basis of treatment and geography. Based on treatment, the global market is segmented into imaging, radiology, and surgeries. The imaging segment of the dysplasia epiphysealis hemimelica treatment market is categorized into computed tomography (CT) scan, magnetic resonance imaging (MRI), and position emission tomography (PET). The radiology approach normally displays an asymmetrical mass with focal ossification rising from one side of the affected epiphysis. The surgical approach includes hip replacement surgery, knee replacement surgery, and surgical excision of mass with preservation of the joint.
Geographically, the dysplasia epiphysealis hemimelica treatment market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market, followed by Europe. The prime factors which have accentuated the growth of the market in these regions are growing awareness about malignant effects of dysplasia epiphysealis hemimelica among the adult population and availability of sophisticated and technologically advanced treatment options. The Asia Pacific market is projected to expand at a high growth rate during the forecast period owing to factors such as high prevalence of dysplasia epiphysealis hemimelica, high population density in South East Asian countries such as China, Malaysia, and Singapore, and strong government support for improved health care infrastructures. Furthermore, emerging economies and easy market penetration in developing Asian countries are projected to drive the market growth in the near future. In Latin America and Middle East & Africa regions, increasing government investments for better health care facilities are expected to drive the market growth.
Key players operating in the global dysplasia epiphysealis hemimelica treatment market are Zimmer Biomet, AstraZeneca, Genentech, Inc., Pfizer Inc., Johnson & Johnson Services, Inc., Novartis AG, Teva Pharmaceutical Industries, Ltd., and Medacta International.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.